logo-loader
viewArtios Pharma Ltd

Artios in strong position to accelerate cancer programmes after Arix investment

Proactive Investors' Andrew Scott sits down with Arix Bioscience Plc's (LON:ARIX) investment director Jonathan Tobin and Niall Martin, chief executive of Artios Pharma.

Arix has recently upped its stake in Artios following a Series B financing round that was backed by the venture capital arms of industry giants Pfizer and Novartis.

Artios Pharma's developing DNA damage response technology to treat cancer.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Xpediator PLC's CFO Robert Ross and COO of Logistics Romania to step up as...

Xpediator PLC's (LON:XPD) CFO Robert Ross speaks to Proactive's Andrew Scott following the news chief executive Stephen Blyth will step down from the position. Blyth will continue as a director in the position of founder and non-executive deputy chairman. While the search for a permanent...

14 hours, 14 minutes ago

2 min read